Regulation and Therapeutic Application of Long non-Coding RNA in Tumor Angiogenesis

Shuo Zhang1,2,3, Yunxiu Xia1,2,3, Weiwei Chen1

  • 1Medical Research Center, Binzhou Medical University Hospital, Binzhou, P.R. China.

Insights

Long non-coding RNAs regulate tumor growth and spread by controlling blood vessel formation (angiogenesis). Targeting these RNAs offers new strategies for anti-angiogenesis cancer therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Tumor growth and metastasis are critically dependent on angiogenesis, the formation of new blood vessels.
  • Long non-coding RNAs (lncRNAs) have emerged as key regulators of tumor angiogenesis.
  • Understanding the precise roles of lncRNAs in this process is crucial for developing effective cancer treatments.

Purpose of the Study:

  • To review the diverse mechanisms by which lncRNAs regulate tumor angiogenesis.
  • To explore the molecular pathways involved in lncRNA-mediated angiogenesis.
  • To summarize novel therapeutic strategies targeting lncRNAs for anti-angiogenesis cancer therapy.

Main Methods:

  • Literature review of studies on lncRNAs and tumor angiogenesis.
  • Analysis of molecular mechanisms underlying lncRNA functions in angiogenesis.
  • Synthesis of current and emerging therapeutic approaches targeting lncRNAs.

Main Results:

  • lncRNAs exhibit multidimensional regulatory roles in tumor angiogenesis.
  • Specific lncRNAs influence endothelial cell behavior, vascular permeability, and tumor microenvironment remodeling.
  • Targeting lncRNAs presents promising avenues for novel anti-angiogenesis therapies.

Conclusions:

  • lncRNAs are pivotal regulators of tumor angiogenesis with significant therapeutic potential.
  • Further research into lncRNA mechanisms can identify new diagnostic biomarkers and treatment targets.
  • Targeting lncRNAs offers a promising strategy to combat tumor growth and metastasis through anti-angiogenesis.

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
5.4K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
21.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K